In this issue:
SELECT-AXIS 2 demonstrates efficacy of upadacitinib for nr-axSpA
Determinants of work and social participation in patients with PsA
Monitoring of disease activity with a smartphone app for axSpA
Recreational physical activity associates with improved global functioning in axSpA
Consensus statements for nonpharmacological management of PsA in UAE
Comparable efficacy of upadacitinib ± non-biologic DMARDs for PsA
Characteristics of patients with axSpA differ significantly by geographic regions
Australian PsA patients prioritise safety over clinical measure of efficacy
Inferior disease control and worse impact of PsA in less wealthy countries
Multiswitch from etanercept to two different biosimilars safe and effective
Please login below to download this issue (PDF)